Prophylactic Effect of Memantine on Chronic Migraine Headache

The effectiveness of adding Memantine to Topiramate in the prevention of headache attacks among patients with chronic migraine headaches

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191205045623N1

Enrollment

Registered

2019-12-26

Start date

2017-04-20

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine headache. Migraine

Interventions

Intervention 1: Intervention group: Patients in intervention group received Memantine tablet 20 mg daily which reached this level after 4 weeks and they received topiramate tablet 50 mg daily as a bas

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 18 to 65 years old Chronic migraine headache according to International Classification of headache

Exclusion criteria

Exclusion criteria: Pregnancy or breast-feeding Renal or hepatic impairment or known cardiovascular disease History of allergy to memantine and topiramate

Design outcomes

Primary

Measure	Time frame
The severity of migraine headache attacks. Timepoint: This evaluation was performed at the beginning of the study, and the end of first, second, third and fourth months of the study. Method of measurement: Visual Analogue Scale.;The disability level of migraine headache attacks. Timepoint: This evaluation was performed at the beginning of the study, and the end of first, second, third and fourth months of the study. Method of measurement: Migraine Disability Assessment Test Survey (MIDAS).;The frequency of migraine headache attacks. Timepoint: This evaluation was performed at the beginning of the study, and the end of first, second, third and fourth months of the study. Method of measurement: Daily headache diary.;The duration of migraine headache attacks. Timepoint: This evaluation was performed at the beginning of the study, and the end of first, second, third and fourth months of the study. Method of measurement: Daily headache diary.	—

Measure

Time frame

The severity of migraine headache attacks. Timepoint: This evaluation was performed at the beginning of the study, and the end of first, second, third and fourth months of the study. Method of measurement: Visual Analogue Scale.;The disability level of migraine headache attacks. Timepoint: This evaluation was performed at the beginning of the study, and the end of first, second, third and fourth months of the study. Method of measurement: Migraine Disability Assessment Test Survey (MIDAS).;The frequency of migraine headache attacks. Timepoint: This evaluation was performed at the beginning of the study, and the end of first, second, third and fourth months of the study. Method of measurement: Daily headache diary.;The duration of migraine headache attacks. Timepoint: This evaluation was performed at the beginning of the study, and the end of first, second, third and fourth months of the study. Method of measurement: Daily headache diary.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDavood Kashipazha

Ahvaz University of Medical Sciences

dakashi47@gmail.com+98 61 3374 3012

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026